ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2202

Trends in Prescribing of NSAIDs and Opioids Among Osteoarthritis Patients in British Columbia, Canada, 1998-2014

Jacek Kopec1, Jolanda Cibere 2, Na Lu 3, Hui Xie 4, J. Antonio Avina-Zubieta 1 and John Esdaile 5, 1Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, 2Arthritis Research Canada and the University of British Columbia, Vancouver, Canada, 3Arthritis Research Canada, Vancouver, BC, Canada, 4Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, 5Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: medication, osteoarthritis and opioids

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Osteoarthritis – Clinical Poster II

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are commonly prescribed for patients with osteoarthritis (OA). However, both types of medication are associated with serious side effects. As a result, guidelines for the treatment of OA have changed substantially over the past 2 decades. Our purpose in this study was to describe the trends in prescribing of NSAIDs (including COX-2 inhibitors) and opioids among patients with OA in the general population.

Methods: We analyzed data from a large, population-based administrative database (PharmaNet) that included all prescriptions for persons aged 50+ processed by pharmacies in the province of British Columbia (BC), Canada, linked to diagnostic codes for visits to physicians and hospitalizations between 1990 and 2014. We identified all incident cases of OA, defined as at least 2 codes within 2 years, with a run-in period of 7 years. We identified all new prescriptions (no prescription in 6 months prior to diagnosis) for each NSAID and opioid available in BC and calculated the proportion of people starting NSAID or opioid medication. We performed similar analyses for prevalent (any) prescriptions among all prevalent cases of OA.

Results: Between 2000 and 2014, the proportion of new OA patients with an NSAID prescription declined from 19.8% to 16.5%. For most NSAIDs (Figure 1), prescriptions declined from 1998 till 2004 and were relatively stable until 2014, with the exception of diclofenac, which increased substantially from 2002 to 2006 and decreased afterwards. In 2014, the most common NSAID was naproxen (5.5%) followed by diclofenac (3.6%), celecoxib (3.2%), ibuprofen (0.9%) and meloxicam (0.5%). For opioids (Figure 2), the overall trend was relatively flat from 1998 to 2004, peaked in 2008 at 24.0%, and declined slightly thereafter. Codeine was by far the most commonly prescribed opioid throughout the study period, but declined from 20.3% of new OA patients in 1998 to 11.9% in 2014. Tramadol increased steadily from its introduction in 2005 and has been the second most common opioid since 2008, reaching 5.3% in 2014. Prescriptions for oxycodone started to decline around 2009 and reached 2.1% in 2014, whereas those for hydromorphone steadily increased to 2.6%. Other opioids were rarely prescribed in patients with OA. The results of prevalence analyses were essentially similar.

Conclusion: There have been important changes in the pattern of prescribing analgesics in BC during the study period. Declines in NSAIDs may have been compensated by increased prescriptions for opioids. This is likely to change as new guidelines discourage the long-term use of opioids as a consequence of the opioid crisis.


OA NSAID graph 2019

Figure 1. Prescriptions for NSAIDs in patients newly diagnosed with OA in British Columbia, Canada, 1998 – 2014


OA opioids graph 2019

Figure 2. Prescriptions for opioids in patients newly diagnosed with OA in British Columbia, Canada, 1998 – 2014


Disclosure: J. Kopec, None; J. Cibere, None; N. Lu, None; H. Xie, None; J. Avina-Zubieta, None; J. Esdaile, None.

To cite this abstract in AMA style:

Kopec J, Cibere J, Lu N, Xie H, Avina-Zubieta J, Esdaile J. Trends in Prescribing of NSAIDs and Opioids Among Osteoarthritis Patients in British Columbia, Canada, 1998-2014 [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/trends-in-prescribing-of-nsaids-and-opioids-among-osteoarthritis-patients-in-british-columbia-canada-1998-2014/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trends-in-prescribing-of-nsaids-and-opioids-among-osteoarthritis-patients-in-british-columbia-canada-1998-2014/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology